Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma


  • B. B. Samura Zaporizhzhia State Medical University Head of the Hematology Department of Zaporizhzhia Regional Clinical Hospital,



VE-catherin, Cardiovascular Events, Multiple Myeloma, Survival, Prognosis


Objective. We aimed to evaluate the prognostic value of circulating VE-catherin for cumulative survival in patients with multiple myeloma in full or partial remission.

Materials and methods. One hundred sixteen patients with multiple myeloma with complete or partial remission were enrolled in the study. Observation period was up to 3 years. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of VE-catherin was used.

Results and Conclusions. During observation period progression of multiple myeloma was proved in 41 patients, 6 persons were excluded for poor follow-up. One hundred ninety three cumulative clinical events occurred in 37 patients (53.6%) within the follow-up, with their distribution being as follows:14 cardiovascular deaths, 90 cardiac arrhythmias, 13 cardiac ischemic events, 6 strokes, 21 chronic heart failures and 49 hospital admissions for cardiovascular reasons. 28 deaths were not related with cardiovascular pathology.

Medians of circulating levels of VE-catherin in free-events subject cohort and subjects cohort with cardiovascular events were 0.51 ng/ml (95% confidence interval [CI]=0.21–0.81 ng/ml) and 1.30 ng/ml (95% CI=0.79–1.81 ng/ml) (р=0.02). In multivariate logistic regression circulating VE-catherin independently predicted cumulative cardiovascular events (odds ratio [OR] = 1.14; 95% CI=1.06–1.17; р=0.001) within 3 years of observation period.

Among patients with documented multiple myeloma in remission increased circulating VE-catherin associates with increased cumulative cardiovascular events.


Cavallaro, U., Leibner, S., & Dejana, E. (2006) Endothelial cadherins and tumor angiogenesis. Exp. Cell Res., 312 (5): 659–667. doi:10.1016/j.yexcr.2005.09.019.

Conway, D. E., Breckenridge, M. T., Hinde, E., Gratton, E., Chen, C. S., & Schwartz, M. A. (2013) Fluid shear stress on endothelial cells modulates mechanical tension across VE-cadherin and PECAM-1. Curr. Biol., 23(11), 1024–1030. doi: 10.1016/j.cub.2013.04.049.

Damiano, J. S., Cress, A. E., Hazlehurst, L. A., Shtil, A. A., & Dalton, W. S. (1999) Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93(5), 1658–1667.

Dimopoulos, M. A, & Terpos, E. (2010) Multiple myeloma. Ann Oncol., 21, 143–150.

Gavard, J. (2013) Endothelial permeability and VE-cadherin: A wacky comradeship. Cell Adh. Migr., 7 (6), 455–461. doi: 10.4161/cam.27330.

George, S. J., & Beeching, C. A. (2006) Cadherin: catenin complex: A novel regulator of vascular smooth muscle cells behaviour. Atherosclerosis, 188(1), 1–11. doi:10.1016/j.atherosclerosis.2005.12.017.

Greipp, P. R., San Miguel, J., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., et al. (2005) International staging system for multiple myeloma. J. Clin. Oncol., 23(15), 3412–3420.

Groen R.W., de Rooij M.F., Kocemba K.A., Reijmers, R. M., de Haan-Kramer, A., Overdijk, M. B., et al. (2011) N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. Haematologica, 96, 1653–1661. doi: 10.3324/haematol.2010.038133.

Gumbiner, B. M. (2005) Regulation of cadherin-mediated adhesion in morphogenesis. Nature Rev. Mol. Cell Biol., 6(8), 622–634. doi:10.1038/nrm1699.

Kraj, M., Sokołowska, U., Kopeć-Szlezak, J., Pogłód, R., Kruk, B., Woźniak, J., & Szpila, T. (2008) Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma, 49(2), 298–305. doi: 10.1080/10428190701760532.

Michigami T., Shimizu N., Williams P.J., Niewolna, M., Dallas, S. L., Mundy, G. R., & Yoneda, T. (2000) Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood, 96(5), 1953–1960.

Mikhael, J. R., Dingli, D., Roy, V., Reeder, C. B., Buadi, F. K., Hayman, S. R. et al. (2013) Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc., 88(7), 360–376. doi: 10.1016/j.mayocp.2013.01.019.

Moreau P., San Miguel J., Ludwig H., Schouten, H., Mohty, M., Dimopoulos, M., Dreyling, M. et al. (2013) ESMO Guidelines Working Group. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol., 24(6), 133–137. doi: 10.1093/annonc/mdt297.

Osborne, T. R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S. A., Sieger, R. J., Edmonds, P. M., & Higginson, I. J. (2014) Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer, 14(1), 496. doi: 10.1186/1471-2407-14-496.

Rubina, K. A., & Takchuk, V. A. (2004) T-cadherin is an atypical low-density lipoprotein receptor in vascular cells. Ross. Fiziol. Zh. Im. I.M. Sechenova, 90(8), 968–986.

Vacca, A., Ria, R., Reale, A. et al. (2014) Angiogenesis in multiple myeloma. Chem Immunol Allergy, 99, 180–196. doi: 10.1159/000353312.

Vandyke K., Chow A.W., Williams S.A., & Zannettino, A. C. (2013) Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma. Br. J. Haematol., 161(4), 499–507. doi: 10.1111/bjh.12280.

Wrobel T., Mazur G., Wolowiec D., Jazwiec, B., Sowinska, E., & Kuliczkowski, K. (2006) sVE-cadherin and sCD146 serum levels in patients with multiple myeloma. Clin. Lab. Haematol., 28(1), 36–39.

Yuregir, O. O., Yurtcu, E., Kizilkilic, E., Kocer, N. E., Ozdogu, H., & Sahin, F. I. (2010) Detecting methylation patterns of p16, MGMT, DAPK and E-cadherin genes in multiple myeloma patients. Int. J. Lab. Hematol., 32(2), 142–149. doi: 10.1111/j.1751-553X.2009.01146.x.

Zhu, X., Zhou, X., Lewis, M. T., Xia, L, & Wong, S. et al. (2011) Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study. J. Theor. Biol., 269(1), 138–149. doi: 10.1016/j.jtbi.2010.10.016.

How to Cite

Samura BB. Circulating VE-catherin and prognosis of cardiovascular events in remission of multiple myeloma. Zaporozhye Medical Journal [Internet]. 2016Sep.6 [cited 2024May20];18(3). Available from:



Original research